An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 May 2019
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim Pharmaceuticals; Unilfarma
- 10 May 2019 Planned End Date changed from 31 Mar 2019 to 31 Oct 2019.
- 31 Oct 2018 Planned End Date changed from 28 Dec 2018 to 31 Mar 2019.
- 31 Aug 2018 Biomarkers information updated